Use of phosphorylated tau and p38gamma to treat a neurological condition

Research output: Patent

Abstract

The present invention relates to a method of treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject, comprising treating the subject to: (a) promote phosphorylation of one or more amino acids residues of tau, wherein the phosphorylation of the amino acid residues causes disruption of the tau-dependent signalling complex in neurons of the subject; or (b) introduce a variant of tau that causes disruption of the tau-dependent signalling complex in neurons of the subject. The invention also relates to vectors, compositions and kits for treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject.

Original languageEnglish
Patent numberUS20190388519
IPCA61P 25/ 28 A I,A61K 38/45
Priority date1/03/17
Publication statusPublished - 26 Dec 2019

Fingerprint Dive into the research topics of 'Use of phosphorylated tau and p38gamma to treat a neurological condition'. Together they form a unique fingerprint.

Cite this